文献速递血栓与止血

英国胎儿医学中心对后续妊娠胎儿和新生儿同种免疫性血小板减少症的产前管理调查

Fetal and neonatal alloimmune thrombocytopenia (FNAIT): Survey of UK fetal medicine centres on antenatal management of subsequent affected pregnancies.
PubMed 文献 · Br J Haematol · 2026-05-19

结果显示,对于抗HPA-1a或抗HPA-5b抗体相关的中危和高危妊娠,强烈共识使用每周静脉注射免疫球蛋白(IVIg),最常用剂量为1 g/kg/周;在高危妊娠中更倾向于早期开始IVIg,而中危妊娠的时机差异较大。皮质类固醇不常规用于中危妊娠,但在高危情景中考虑使用;胎儿血样采集和宫内血小板输注通常避免。分娩计划及无既往确诊的妊娠管理存在显著差异。

要点

  • 对标准和高危抗HPA-1a或抗HPA-5b妊娠,强烈共识使用每周IVIg,最常见1 g/kg/周。
  • 高危妊娠倾向更早启动IVIg,标准风险妊娠启动时机差异较大。
  • 皮质类固醇不常规用于标准风险妊娠,高危情景可考虑;通常避免胎儿血样和宫内输注。

核心结论

  • 英国胎儿医学中心对FNAIT后续妊娠的产前管理在IVIg使用上存在一致性,但在分娩计划和无既往确诊妊娠的管理上存在显著差异。

主要发现

  • 对标准和高危抗HPA-1a或抗HPA-5b相关妊娠,强烈共识(≥75%一致)使用每周IVIg,最常见剂量为1 g/kg/周。
  • 高危妊娠更倾向于早期启动IVIg,而标准风险妊娠的启动时机差异较大。
  • 皮质类固醇不常规用于标准风险妊娠,但在高危情景中考虑使用。
  • 胎儿血样采集和宫内血小板输注通常避免。
  • 分娩计划及无既往确诊的妊娠管理存在显著差异。

关键数值与推荐

  • 一致率≥75%定义为强烈共识。
  • 对标准和高危抗HPA-1a或抗HPA-5b妊娠,强烈共识使用每周IVIg,最常见剂量为1 g/kg/周。

临床怎么用

  • 英国多数中心对FNAIT后续标准和高危妊娠采用每周IVIg(常见1 g/kg/周),高危妊娠可更早启动。
  • 皮质类固醇不常规用于标准风险妊娠,高危情景可考虑;通常避免胎儿血样和宫内血小板输注。
  • 分娩计划和无既往确诊妊娠的管理需进一步研究以形成指南。

局限性

  • 研究为情景式问卷调查,反映的是临床实践而非患者结局。
  • 证据基础存在缺口,部分管理领域差异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition associated with severe fetal thrombocytopenia and intracerebral haemorrhage. Antenatal management of subsequent pregnancies relies on intravenous immunoglobulin (IVIg); yet, practice varies internationally and UK data are limited. We conducted a national survey to characterise the current antenatal management of FNAIT across UK regional fetal medicine centres using an electronic, scenario-based design. Responses were analysed descriptively, with ≥75% concordance considered strong agreement. Sixteen of 22 regional fetal medicine centres (73%) responded; all respondents were fetal medicine specialists or haematologists. There was strong consensus to treat standard- and high-risk pregnancies associated with anti-human platelet antigen (HPA)1a or anti-HPA5b antibodies using weekly IVIg, most commonly at a dose of 1 g/kg/week. Earlier initiation of IVIg was favoured for high-risk pregnancies, while timing was more variable for standard-risk cases. Corticosteroids were not routinely used in standard-risk pregnancies but were considered in high-risk scenarios. Fetal blood sampling and intrauterine platelet transfusion were generally avoided. Considerable variation was observed in delivery planning and in the management of pregnancies at risk without a prior confirmed diagnosis. This survey demonstrates the areas of both consistency and variation in UK practice, highlighting gaps in the evidence base and priorities for future research and guidelines development.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Aggarwal A, Prodger C, Hockley B, et al. Fetal and neonatal alloimmune thrombocytopenia (FNAIT): Survey of UK fetal medicine centres on antenatal management of subsequent affected pregnancies. Br J Haematol. 2026. PMID: 42156238. doi:10.1111/bjh.70564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。